http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2836394-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
filingDate 2012-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdf36172b22f3ecd659c22bd58ffdbe6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42ec6b5aede1972684114d448e4dd970
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ffe8febcf1c4aab2c50a058c5164b70
publicationDate 2012-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2836394-A1
titleOfInvention Novel ticagrelor co - crystal
abstract The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is acetyl salicylic acid, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a such a co-crystal.
priorityDate 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415967396
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421221977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439207
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454668499
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415966237
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23452462
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451905405
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9871419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474773
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID34312
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450683113
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID153694064
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121950
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527521
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID428961227
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556224
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID34312
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6022
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID95497
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57503849

Total number of triples: 55.